Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin vs Metformin Dose Escalation in Type 2 Diabetes
jRCT1011220005Completed
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) comparing Imeglimin addition with Metformin dose escalation (2 arms). Primary endpoint: Change in HbA1c from baseline at 24 weeks. Started Sep 2022; status: completed.
02
Drugs
imegliminmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1011220005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011220005.